A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe.
Pharmaceuticals (Basel, Switzerland) – December 28, 2022
Source: PubMed
Summary
Groundbreaking advances in synthetic chemistry are making psychedelic compounds from Psilocybe mushrooms more accessible for clinical research. Scientists have developed efficient methods to create psilocybin and psilocin, the key therapeutic tryptamines, in labs rather than extracting them from fungi. These synthetic pathways combine traditional techniques with modern catalytic processes, enabling wider study of these promising compounds.
Abstract
Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and efficient synthetic routes. We review here the various syntheses used to obtain these molecules, focusing first on the classic historical syntheses, then the use of more recent metallo-catalyzed couplings and finally the known biocatalytic methods for obtaining these molecules. Other access routes are certainly possible and should be the subject of future research given the therapeutic interest of these compounds.